Alembic Pharmaceuticals (NSEI:APLLTD) - Aktienkurs, Nachrichten und Analyse

APLLTD Aktienübersicht

Alembic Pharmaceuticals Limited entwickelt, produziert und vermarktet pharmazeutische Produkte in Indien und international. Mehr Details

APLLTD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	4/6
Vergangene Leistung	4/6
Finanzielle Gesundheit	6/6
Dividenden	3/6

Belohnungen

Das Kurs-Gewinn-Verhältnis (31.5x) liegt unter dem Branchendurchschnitt Pharmaceuticals (32.2x)

Prognostiziertes Gewinnwachstum 21.48% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 21.6%

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Dividende von 1.06% ist nicht gut durch freie Cashflows gedeckt

Alembic Pharmaceuticals Limited Wettbewerber

Jubilant Pharmova

BSE:530019

₹179.1b

Concord Biotech

NSEI:CONCORDBIO

₹208.3b

Neuland Laboratories

BSE:524558

₹189.8b

Emcure Pharmaceuticals

NSEI:EMCURE

₹242.7b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Alembic Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	₹1,037.85
52-Wochen-Hoch	₹1,303.90
52-Wochen-Tief	₹710.25
Beta	0.69
11 Monat Veränderung	-4.81%
3 Monate Veränderung	-5.76%
1 Jahr Veränderung	43.66%
33 Jahre Veränderung	31.49%
5 Jahre Veränderung	82.95%
Veränderung seit IPO	2,073.51%

Aktuelle Nachrichten und Updates

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Nov 10

Recent updates

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Nov 10

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Sep 25

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Sep 03

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 13

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Jul 20

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Jun 03

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

May 11

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20

Aktionärsrenditen

	APLLTD	IN Pharmaceuticals	IN Markt
7D	1.0%	-0.2%	0.3%
1Y	43.7%	40.5%	27.3%

Rendite im Vergleich zur Industrie: APLLTD übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 40.5 erzielte.

Rendite vs. Markt: APLLTD übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 27.3 erzielte.

Preisvolatilität

Is APLLTD's price volatile compared to industry and market?
APLLTD volatility
APLLTD Average Weekly Movement	5.6%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.1%
10% most volatile stocks in IN Market	9.2%
10% least volatile stocks in IN Market	4.0%

Stabiler Aktienkurs: APLLTD hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: APLLTDDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1907	14,858	Chirayu Amin	alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited entwickelt, produziert und vermarktet pharmazeutische Produkte in Indien und international. Das Unternehmen bietet Markenspezialitäten in verschiedenen therapeutischen Bereichen wie Kardiologie, Gynäkologie, Gastrologie, Ophthalmologie, Dermatologie, Nephrologie/Urologie, Orthopädie, Antiinfektiva, Erkältungs- und Hustenmittel, Tierarzneimittel und Antidiabetika, Generika in Form von festen Arzneimitteln zum Einnehmen, festen Arzneimitteln zum Einnehmen in der Onkologie und injizierbaren Arzneimitteln, allgemeinen injizierbaren Arzneimitteln und Augenarzneimitteln, Dermatologie und Suspensionen zum Einnehmen sowie aktive pharmazeutische Wirkstoffe. Das Unternehmen exportiert auch seine Produkte.

Alembic Pharmaceuticals Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Alembic Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
APLLTD grundlegende Statistiken
Marktanteil	₹204.00b
Gewinn(TTM)	₹6.47b
Umsatz(TTM)	₹63.57b

31.5x

Kurs-Gewinn-Verhältnis

3.2x

Kurs-Umsatz-Verhältnis

Ist APLLTD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
APLLTD Gewinn- und Verlustrechnung (TTM)
Einnahmen	₹63.57b
Kosten der Einnahmen	₹17.44b
Bruttogewinn	₹46.13b
Sonstige Ausgaben	₹39.66b
Umsatz	₹6.47b

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	32.90
Bruttomarge	72.56%
Nettogewinnspanne	10.17%
Schulden/Eigenkapital-Verhältnis	20.4%

Wie hat sich APLLTD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.1%

Aktuelle Dividendenrendite

35%

Ausschüttungsquote

APLLTD Aktienübersicht

Belohnungen

Risikoanalyse

Alembic Pharmaceuticals Limited Wettbewerber

BSE:530019

₹179.1b

NSEI:CONCORDBIO

₹208.3b

BSE:524558

₹189.8b

NSEI:EMCURE

₹242.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules

Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024

Now 21% overvalued after recent price rise

Recent updates

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules

Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024

Now 21% overvalued after recent price rise

Alembic Pharmaceuticals Limited Announces USFDAFinal Approval for Lamotrigine Extended-Release Tablets Usp, 200 mg, 250 mg, and 300 mg

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations

Investor sentiment improves as stock rises 17%

Price target increased by 7.2% to ₹1,056

Now 25% overvalued after recent price rise

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12%

Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head ­ Legal

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial

Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07%

Upcoming dividend of ₹11.00 per share

Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg

Now 21% overvalued

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dividend increased to ₹11.00

Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024

Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business)

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Now 20% overvalued

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023)

Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals

Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Third quarter 2024 earnings: Revenues in line with analyst expectations

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Investor sentiment improves as stock rises 17%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals

Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy

Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel

Price target increased by 10% to ₹659

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Upcoming dividend of ₹8.00 per share at 1.2% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal

Erträge & Einnahmen